JP7854948B2 - Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法 - Google Patents

Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Info

Publication number
JP7854948B2
JP7854948B2 JP2022578860A JP2022578860A JP7854948B2 JP 7854948 B2 JP7854948 B2 JP 7854948B2 JP 2022578860 A JP2022578860 A JP 2022578860A JP 2022578860 A JP2022578860 A JP 2022578860A JP 7854948 B2 JP7854948 B2 JP 7854948B2
Authority
JP
Japan
Prior art keywords
antigen
cancer
amino acid
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022578860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532852A (ja
JP2023532852A5 (enExample
Inventor
ジェニファー トンラン ウー，
Original Assignee
キャンキュア， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャンキュア， エルエルシー filed Critical キャンキュア， エルエルシー
Publication of JP2023532852A publication Critical patent/JP2023532852A/ja
Publication of JP2023532852A5 publication Critical patent/JP2023532852A5/ja
Priority to JP2025169285A priority Critical patent/JP2026021336A/ja
Application granted granted Critical
Publication of JP7854948B2 publication Critical patent/JP7854948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
JP2022578860A 2020-07-07 2021-07-06 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法 Active JP7854948B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025169285A JP2026021336A (ja) 2020-07-07 2025-10-07 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049012P 2020-07-07 2020-07-07
US63/049,012 2020-07-07
PCT/US2021/040445 WO2022010847A1 (en) 2020-07-07 2021-07-06 Mic antibodies and binding agents and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025169285A Division JP2026021336A (ja) 2020-07-07 2025-10-07 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2023532852A JP2023532852A (ja) 2023-08-01
JP2023532852A5 JP2023532852A5 (enExample) 2024-07-10
JP7854948B2 true JP7854948B2 (ja) 2026-05-07

Family

ID=77127088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022578860A Active JP7854948B2 (ja) 2020-07-07 2021-07-06 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法
JP2025169285A Pending JP2026021336A (ja) 2020-07-07 2025-10-07 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025169285A Pending JP2026021336A (ja) 2020-07-07 2025-10-07 Ｍｉｃ抗体及び結合剤ならびにそれらの使用方法

Country Status (9)

Country Link
US (2) US12139539B2 (enExample)
EP (1) EP4178678A1 (enExample)
JP (2) JP7854948B2 (enExample)
KR (2) KR102594083B1 (enExample)
CN (1) CN116249716A (enExample)
AU (1) AU2021305084A1 (enExample)
CA (1) CA3184940A1 (enExample)
TW (1) TWI925854B (enExample)
WO (1) WO2022010847A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4423140A4 (en) * 2021-10-27 2025-10-01 Samyang Biopharm Usa Inc ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS
WO2023225626A2 (en) * 2022-05-20 2023-11-23 Adanate, Inc. Multi-targeting lilrb antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523929A (ja) 2013-07-05 2016-08-12 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
EP1082411A2 (en) 1998-06-02 2001-03-14 Dendreon Corporation Method for preparation and in vivo administration of antigen presenting cell composition
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
CA2388432A1 (en) 1999-10-21 2001-04-26 Monsanto Company Post-translational modification of recombinant proteins produced in plants
AU1811801A (en) 1999-12-03 2001-06-12 Dendreon Corporation Cryopreservation of antigen-loaded dendritic cells and their precursors in serum-free media
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US7060279B2 (en) 2000-03-30 2006-06-13 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US20080196111A1 (en) 2005-03-18 2008-08-14 Innate Pharma S.A. Expression Vectors and Methods for Obtaining Nk Cell Specific Expression
US20100111973A1 (en) 2006-09-22 2010-05-06 Glenn Dranoff Methods for treating mica-related disorders
ES2550384T3 (es) 2008-12-18 2015-11-06 Dana-Farber Cancer Institute, Inc. NKG2D-Fc para la inmunoterapia
WO2012091756A1 (en) 2010-12-30 2012-07-05 Avidbiotics Corp. Non-natural mic proteins
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
US8753640B2 (en) * 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
DK2760471T3 (en) 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
JP6405242B2 (ja) 2012-02-07 2018-10-17 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｍｉｃａ結合剤
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
WO2015179627A1 (en) 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
EP3712171A1 (en) 2014-08-19 2020-09-23 Novartis AG Treatment of cancer using a cd123 chimeric antigen receptor
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
EP3288569A4 (en) 2015-04-29 2018-12-19 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
ES2958720T3 (es) 2015-06-10 2024-02-13 Immunitybio Inc Células NK-92 modificadas para tratar el cáncer
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
AU2016366677A1 (en) 2015-12-09 2018-07-26 Nantcell, Inc. Compositions and methods for treatment of HER2 positive metastatic breast cancer
WO2018073648A1 (en) 2016-10-19 2018-04-26 Novelogics Biotechnology, Inc. Antibodies to mica and micb proteins
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
AU2018231193B2 (en) 2017-03-08 2021-07-22 Immunitybio, Inc. Modified NK-92 haNK003 cells for the clinic
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
WO2019004550A1 (ko) 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
US12036241B2 (en) 2017-07-19 2024-07-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
KR20200035999A (ko) 2017-08-04 2020-04-06 난트케이웨스트, 인크. Nk-92 세포를 이용한 백혈병의 치료 및 억제
EP4516896A3 (en) 2017-08-09 2025-05-14 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
KR102832008B1 (ko) 2018-07-31 2025-07-10 컬리난 미카 코퍼레이션 Mica/b 유출을 차단하는 항-mica/b 항체 및 사용 방법
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
CN113330026A (zh) * 2018-10-23 2021-08-31 美真达治疗公司 Fc沉默的抗体药物缀合物(ADC)及其用途
EP4017876A4 (en) 2019-08-23 2023-09-06 Northwestern University MATERIALS AND METHODS FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES
EP4423140A4 (en) 2021-10-27 2025-10-01 Samyang Biopharm Usa Inc ANTI-MIC ANTIBODIES WITH VARIANT FC DOMAINS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523929A (ja) 2013-07-05 2016-08-12 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体

Also Published As

Publication number Publication date
KR20230012072A (ko) 2023-01-25
EP4178678A1 (en) 2023-05-17
US12139539B2 (en) 2024-11-12
JP2026021336A (ja) 2026-02-10
KR102594083B1 (ko) 2023-10-25
US20230235065A1 (en) 2023-07-27
TWI925854B (zh) 2026-05-21
WO2022010847A1 (en) 2022-01-13
US20250026837A1 (en) 2025-01-23
TW202216776A (zh) 2022-05-01
AU2021305084A1 (en) 2023-02-02
CA3184940A1 (en) 2022-01-13
JP2023532852A (ja) 2023-08-01
KR20230152783A (ko) 2023-11-03
CN116249716A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
AU2015374301B2 (en) Anti-CD47 antibodies and uses thereof
CN112566935B (zh) 抗ox40抗体和使用方法
DK2595662T3 (en) Anti-CD19 antibody with ADCC and CDC functions and improved glycosylation profile
EP2760891B1 (en) Hybrid constant regions
CA3141626A1 (en) Novel il-15 prodrugs and methods of use thereof
US20250026837A1 (en) MIC Antibodies and Binding Agents and Methods of Using the Same
AU2017228055A1 (en) Antibodies specific to human poliovirus receptor (PVR)
CA2879814A1 (en) Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
AU2019378101A1 (en) Humanized anti-SIRPα antibodies
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
CA3192208A1 (en) Anti-par-2 antibodies and methods of use thereof
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
Pandey et al. Monoclonal antibodies as therapeutics in human malignancies
JP2025527535A (ja) 抗ｃｃｒ８抗体およびその使用
JP2025538606A (ja) 抗ｃｃｒ８抗体及びその使用
CN117279954A (zh) 抗人cxcr5抗体及其用途
EA039429B1 (ru) Способы лечения опухолей с применением биспецифического антитела cd3xcd20
HK40087490A (en) Mic antibodies and binding agents and methods of using the same
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
CN114269780B (zh) 一种新型抗pd-l1抗体及其用途
WO2024044675A1 (en) Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
HK40104546A (en) Anti-human cxcr5 antibody and uses thereof
TW202446419A (zh) 使用抗ｏｘ４０抗體與抗ｐｄ１抗體之組合的癌症治療方法
CN120917047A (zh) 抗cldn6和抗cd3多特异性抗体及其使用方法
EA052797B1 (ru) Биспецифичные антитела, содержащие домен, связывающий nrp1, и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260421

R150 Certificate of patent or registration of utility model

Ref document number: 7854948

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150